Travelan Experiences Strong Q1 FY2018 Sales Growth
Filed with ASX · · 2 pages · English
Earlier from Immuron
- Appendix 4E Preliminary Final Report (30 June 2017)
- Immuron Opens Clinical Site to Commence C.Diff CDI Study
- Immuron Approved to Commence Clinical Study in C.Difficile
- Immuron to Present C.difficile Data at ClostPath 2017 Confer
- Immuron Announces Management Changes
Later from Immuron
- Immuron Successfully Completes NASH Phase II Clinical Study
- Immuron Granted US Patent for NASH Treatment
- Immuron to Receive $2.16M R&D Tax Concession Cash Refund
- US Defence Depart Report-Travelan Targets Priority Pathogens
- Travelan Revenue Grows Significantly in US and Australia
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron